Inventiva declares results of Phase IIb clinical trial of lanifibranor
Category: #health  By Mateen Dalal  Date: 2019-02-19
  • share
  • Twitter
  • Facebook
  • LinkedIn

Inventiva declares results of Phase IIb clinical trial of lanifibranor

The FASST clinical trial failed to meet its primary endpoint of a mean absolute change from baseline to week 48

The French clinical-stage biopharmaceutical firm Inventiva has reportedly declared the results from the ‘For A Systemic Sclerosis Treatment’ (FASST) clinical trial assessing lanifibranor for the treatment of diffuse cutaneous systemic sclerosis (dcSSc). As per trusted sources, the FASST clinical trial failed to meet its primary endpoint of a mean absolute change from baseline to week 48.

Reportedly, the FASST clinical trial included 145 patients suffering from the initial phase of dcSSc. These patients received lanifibranor in either two dosages of 600mg each day or two dosages of 400mg each day over a period of 48 weeks. Sources familiar with the matter claim that the dosages were in addition to the existing standard of care and included immunosuppressive therapy in most cases. For the record, the FASST clinical trial is a placebo-controlled, randomized, double-blind, one-year Phase IIb study.

Co-principal investigator of the FASST clinical trial and professor of rheumatology at the Hôpital Cochin in Paris, Yannick Allanore was reportedly quoted saying that the trail characterizes the first study in dcSSc with a stratified background on immunosuppressive therapy. Allanore further added that the presence of background therapy created a strong placebo effect and restricted the number of patients making progress in dcSSc.

According to a press release issued by Inventiva, over the course of the trial, the average mRSS declined in active and placebo arms with only four patients reporting to have observed increase in mRSS scores.

Co-principal investigator of the FASST clinical trial and professor at the University College of London, Christopher Denton reportedly commented that the team regrets the outcome of the study. However, lanifibranor’s favorable safety profile observed in the trial and the well-being of lanifibranor patients expressed in the global assessment has been a gratifying experience for the team.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Health insurer Alan acquires Jour to enter the mental health market
Health insurer Alan acquires Jour to enter the mental health market
By Mateen Dalal

Alan, a health insurance startup based in France, has acquired American digital behavioral health firm, Jour for $20 million. The acquisition has assisted the French health insurer to launch its new digital health service, Alan Mind, helping it ...

WAVE Electronics adds CYNC™ Smart Home solutions to its portfolio
WAVE Electronics adds CYNC™ Smart Home solutions to its portfolio
By Mateen Dalal

South Korean consumer equipment firm, WAVE Electronics has recently formed an alliance with home automation company, Savant Systems, Inc. to provide CYNC™ smart home solutions to its contractors, custom installation professionals, and builders ...

WardWizard Innovations & Mobility to invest $20Mn in EV business
WardWizard Innovations & Mobility to invest $20Mn in EV business
By Mateen Dalal

Indian electric vehicle manufacturer, WardWizard Innovations and Mobility have expressed plans to spend INR 150 crore (USD 20 million) in the coming six months in its EV business, as it seeks to ramp up technology and infrastructure, among other thin...